^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    FG-3246

    i
    Other names: FG-3246, FOR46, FOR 46, FG3246, FG 3246, FOR-46
    Associations

    News

    Trials
    Company:
    FibroGen, Fortis Therap
    Drug class:
    Microtubule inhibitor, CD46-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    3d
    A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=75, Not yet recruiting, FibroGen | Trial completion date: Sep 2027 --> Mar 2028 | Initiation date: Apr 2025 --> Sep 2025 | Trial primary completion date: Sep 2027 --> Mar 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    CD46 (CD46 Molecule)
    |
    FG-3246
    4ms
    Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer. (PubMed, J Clin Oncol)
    FOR46 demonstrated encouraging preliminary clinical activity with a manageable safety profile. Targeting CD46 elicited an immune priming effect that was associated with clinical outcomes.
    P1 data • Journal
    |
    CD8 (cluster of differentiation 8) • CD46 (CD46 Molecule)
    |
    Xtandi (enzalutamide) • FG-3246
    5ms
    A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=75, Not yet recruiting, FibroGen
    New P2 trial
    |
    CD46 (CD46 Molecule)
    |
    FG-3246
    over1year
    A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P1, N=56, Completed, Fortis Therapeutics, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    CD46 (CD46 Molecule)
    |
    FG-3246
    almost5years
    A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    Trial completion date: Jun 2020 --> Dec 2021 | Trial primary completion date: Apr 2020 --> Apr 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
    |
    FG-3246